Erythropoietin, often referred to as Epo, is a hormone generated by the kidneys in response to decreased oxygen levels in the bloodstream. It acts as a stimulus for the bone marrow to produce red blood cells (RBCs). In the context of chronic kidney failure, anemia primarily develops due to the insufficient production of erythropoietin by diseased kidneys. To address this deficiency, medical practitioners employ erythropoiesis-stimulating agent (ESA) therapy, including substances like Epoetin alfa, Epogen®, and Procrit®. This therapy allows healthcare providers to maintain patients’ hemoglobin levels (a crucial oxygen-carrying protein within RBCs) within the recommended range.
